WHITEHALL PRIMATENE TABLETS, DRISTAN SPRAY LABELING PROBLEMS
This article was originally published in The Tan Sheet
Executive Summary
WHITEHALL PRIMATENE TABLETS, DRISTAN SPRAY LABELING PROBLEMS are cited in a Feb. 25 FDA warning letter that follows up on a Jan. 20-Feb. 1 inspection of Whitehall-Robins Labs' Madison, N.J. manufacturing facility. The warning letter notes that lots of Primatene Tablets were distributed between February and December 1993 with labeling "which failed to include the required pregnancy warning statement." Lots of Dristan 12-Hour Nasal Decongestant Spray were distributed between April and September 1993 with labeling "which failed to include the heart ailment/disease warning," the letter states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning